Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease
- PMID: 33203951
- DOI: 10.1038/s41409-020-01122-8
Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease
Abstract
Glucocorticoid-refractory (SR) chronic (c) graft-versus-host disease (GVHD) is a multisystem immunological disease and the leading cause of non-relapse mortality (NRM) in patients surviving longer than 2 years after allogeneic hematopoietic cell transplantation. Both ruxolitinib (RUX) and extracorporeal photopheresis (ECP) have shown activity for SR-cGVHD which motivated us to treat refractory cGHVD patients with the RUX-ECP combination. In this retrospective survey, 23 patients received RUX-ECP as salvage therapy for SR-cGVHD. The best response (CR or PR) at any time point during treatment was 74% (17/23) including 9% (2/23) CR and 65% (15/23) PR. The 24-months-survival was 75% (CI 56.0-94.1). Newly diagnosed cytopenia occurred in 22% (5/23) and CMV reactivation was observed in 26% (6/23) of the patients. Serum levels of soluble interleukin-2 receptor (sIL-2R) correlated with response. Our retrospective analysis shows that the RUX-ECP combination is safe and has activity in a fraction of patients with SR-cGVHD, which needs validation in a prospective trial.
Similar articles
-
ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.Bone Marrow Transplant. 2024 Mar;59(3):380-386. doi: 10.1038/s41409-023-02174-2. Epub 2024 Jan 6. Bone Marrow Transplant. 2024. PMID: 38184740 Free PMC article.
-
Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population.Leuk Res. 2024 Dec;147:107611. doi: 10.1016/j.leukres.2024.107611. Epub 2024 Oct 29. Leuk Res. 2024. PMID: 39500129
-
The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.Curr Res Transl Med. 2020 Apr;68(2):71-76. doi: 10.1016/j.retram.2019.10.001. Epub 2019 Oct 17. Curr Res Transl Med. 2020. PMID: 31631014
-
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.Cochrane Database Syst Rev. 2022 Jun 9;6(6):CD009898. doi: 10.1002/14651858.CD009898.pub4. Cochrane Database Syst Rev. 2022. PMID: 35679154 Free PMC article. Review.
-
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.Cochrane Database Syst Rev. 2014 Feb 25;(2):CD009898. doi: 10.1002/14651858.CD009898.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2015 Dec 15;(12):CD009898. doi: 10.1002/14651858.CD009898.pub3. PMID: 24569961 Updated. Review.
Cited by
-
Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.J Am Acad Dermatol. 2024 Jan;90(1):19-36. doi: 10.1016/j.jaad.2022.12.023. Epub 2022 Dec 23. J Am Acad Dermatol. 2024. PMID: 36572064 Free PMC article. Review.
-
Novel Treatment for Graft-versus-Host Disease.Blood Cell Ther. 2021 Nov 25;4(4):101-109. doi: 10.31547/bct-2021-022. eCollection 2021 Nov 25. Blood Cell Ther. 2021. PMID: 36714067 Free PMC article.
-
ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.Bone Marrow Transplant. 2024 Mar;59(3):380-386. doi: 10.1038/s41409-023-02174-2. Epub 2024 Jan 6. Bone Marrow Transplant. 2024. PMID: 38184740 Free PMC article.
-
Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers.Front Immunol. 2023 Feb 17;14:1086006. doi: 10.3389/fimmu.2023.1086006. eCollection 2023. Front Immunol. 2023. PMID: 36875063 Free PMC article. Review.
-
Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.Hemasphere. 2021 Jun 1;5(6):e581. doi: 10.1097/HS9.0000000000000581. eCollection 2021 Jun. Hemasphere. 2021. PMID: 34095764 Free PMC article. Review.
References
-
- Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M. et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53. https://doi.org/10.1056/NEJMoa1506002 . - DOI - PubMed
-
- Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118:4242–9. https://doi.org/10.1182/blood-2011-03-344390 . - DOI - PubMed - PMC
-
- Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108:2867–73. https://doi.org/10.1182/blood-2006-02-003954 . - DOI - PubMed - PMC
-
- Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117:4651–7. https://doi.org/10.1182/blood-2010-11-319509 . - DOI - PubMed - PMC
-
- Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015;21:389–401. https://doi.org/10.1016/j.bbmt.2014.12.001 . - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials